^
Association details:
| Biomarker: | FGFR3 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | rogaratinib (BAY 1163877) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.
Excerpt:
Selected patients were treated with rogaratinib 800mg twice daily...Eleven of 12 pts with a PR were positive for FGFR3 mRNA, 5 of whom also had FGFR3 mutations, and one patient was positive for FGFR1 mRNA.
DOI:
10.1200/JCO.2018.36.6_suppl.494
Trial ID:
